Galectin Therapeutics Inc. (GALT) Stock Score, Valuation & Financial Research

Galectin Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for GALT

Galectin Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 3.88. These figures are a research snapshot, not a buy or sell recommendation.

What Galectin Therapeutics Inc. does

Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Galectin Therapeutics is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and other financing activities to fund the research and development of carbohydrate-based drug candidates targeting galectin proteins for the treatment of fibrotic diseases and cancer.

Products and services

  • The company is developing belapectin, a galectin-3 inhibitor, for the treatment of advanced liver fibrosis and liver cirrhosis in MASH patients, alongside a discovery program for other small molecule galectin inhibitors.

Customer types

Clinical trial participants and medical research institutions.

Suppliers, materials and equipment

  • Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs) — The company relies on third-party service providers for clinical trial management, drug substance manufacturing, and other development services; specific supplier names are not disclosed. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for MASH, liver fibrosis, and cancer, including those with larger financial resources and established commercial infrastructure. Source

Business strengths to evaluate

  • Proprietary carbohydrate-based drug candidate platform targeting galectin proteins Source
  • Extensive intellectual property portfolio including granted U.S. and foreign patents Source

Business risks and research considerations

  • History of operating losses and dependence on future financing to continue operations Source
  • Uncertainty regarding the success of clinical trials and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

GALT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 3.88
Market capitalization:
255.52M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -27.84M
Free cash flow:
USD -23.88M
Cash:
USD 13.27M
Total debt:
USD 137.7M
EPS:
USD -0.43

What stands out

  • Free cash flow is USD -23.88M, negative for the stored period.
  • The balance sheet shows USD 13.27M of cash versus USD 137.7M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 124.43M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for GALT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can GALT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is GALT's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for GALT to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of GALT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research GALT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.